SCHEMBL18060977

SCHEMBL18060977

CCC(=O)Nc1cccc(Sc2c(C)nc(N3CCNCC3)nc2C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ ITGA2B P08514 4/20 0.46
▸ ITGB3 P05106 3/20 0.46
▸ AURKA O14965 2/20 0.45
▸ AURKB Q96GD4 2/20 0.45
▸ CHEK1 O14757 1/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ PAK4 O96013 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ LCK P06239 1/20 0.43
▸ FYN P06241 1/20 0.43
▸ CSF1R P07333 1/20 0.43
▸ RET P07949 1/20 0.43
▸ IGF1R P08069 1/20 0.43
▸ MET P08581 1/20 0.43
▸ PDGFRB P09619 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12806188 0.89 NPC1 (0.51) KMT2AMEN1AURKAAURKBABL1
SCHEMBL12805461 0.89 SIRT2 (0.39) KMT2AMEN1ITGA2BITGB3AURKA
SCHEMBL18977905 0.87 KMT2A (0.46) KMT2AMEN1ITGA2BITGB3AURKA
SCHEMBL12806382 0.85 TDP1 (0.41) KMT2AMEN1JAK3SIRT2POLB
SCHEMBL12805725 0.77 AURKB (0.44) ITGA2BITGB3AURKAAURKBCHEK1
SCHEMBL1275994 0.77 NPC1 (0.48) KMT2AMEN1AURKAAURKBABL1
SCHEMBL18060670 0.76 KCNQ3 (0.47) KMT2AMEN1RAB9APOLBNPC1
SCHEMBL12806384 0.75 CTSB (0.40) KMT2AJAK3BTKHTR1A
SCHEMBL28089438 0.74 ITGB3 (0.55) KMT2AMEN1ITGA2BITGB3AURKA
SCHEMBL12806115 0.74 MAPT (0.43) KMT2AMEN1CDK9RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3205647-B1 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2020-05-13 — — EP disclosed
EP-3205647-A2 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Memorial Sloan-Kettering Cancer Center (US) 2017-08-16 — — EP disclosed
EP-2467142-B1 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders SLOAN KETTERING INST CANCER (US) 2016-09-21 — — EP disclosed
Send feedback